Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
Invasive breast cancer is a complex and multifaceted disease that continues to pose significant challenges in the field of oncology. Characterized by the infiltration of malignant cells beyond the myoepithelial and basement membrane layers, invasive breast cancer allows these cells to invade the surrounding breast stroma. At Alfa Cytology, our team of experienced biologists work with you to develop breast cancer therapeutics.
Invasive breast cancer remains a significant public health concern, with an estimated 2.3 million new cases and 684,000 deaths worldwide in 2020. The incidence and mortality rates vary across different regions, with developed countries generally reporting higher incidence but lower mortality compared to developing countries. In the United States, breast cancer is the most common cancer among women, with an estimated 284,200 new cases and 44,130 deaths in 2021. As the complexity and heterogeneity of invasive breast cancer continue to pose significant challenges in the field of oncology, the development of targeted therapeutic molecules has become increasingly crucial.
Fig.1 Distribution of invasive breast cancer cases by the age at diagnosis for each race/ethnicity cohort according to 2014-2017 SEER 21 data. (Hendrick R. E., et al. 2021)
Invasive breast cancer encompasses a diverse spectrum of subtypes, each with its own distinct molecular signatures and clinical characteristics. This heterogeneity poses a significant challenge, as it requires a tailored approach to treatment. Researchers are actively involved in several clinical trials exploring innovative approaches to the treatment of invasive breast cancer.
| NCT | Therapeutics | Descriptions | Phase |
| NCT02077569 | AZD5363 | AKT Pathway Inhabitor | |
| NCT03564782 | PVSRIPO | PVSRIPO is the live attenuated, oral (Sabin) serotype 1 poliovirus vaccine containing a heterologous internal ribosomal entry site (IRES) derived from the human rhinovirus type 2 (HRV2). | |
| NCT01088893 | Everolimus | mTOR Inhibition |
Alfa Cytology, a leading preclinical CRO, offers a comprehensive suite of services to support research and development efforts in invasive breast cancer. Our expertise extends across the entire drug discovery and development pipeline, including in vitro assays, in vivo models, biomarker analysis, and specialized testing capabilities. We collaborate closely with academic institutions, pharmaceutical companies, and biotechnology firms to design and execute tailored preclinical studies that provide valuable insights and accelerate the progress of innovative therapies.
Alfa Cytology is committed to providing comprehensive solutions for different invasive breast cancers.
As the field of oncology continues to evolve, Alfa Cytology remains at the forefront of innovative treatment development for invasive breast cancer. Through integrated approaches, cutting-edge preclinical models and biomarker-driven strategies, we are committed to advancing this critical area of cancer research. By collaborating with Alfa Cytology, clients gain access to a comprehensive suite of services tailored to the unique needs of invasive breast cancer research and development. If you are interested in our service, please contact us.
Reference
